Testing melatonin and low-dose quetiapine for insomnia in patients with psychiatric disorders
Official title: Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia: a Randomized Clinical Trial
Run by University of Copenhagen · NCT06062953 · Data updated 2026-11-12
This study is testing whether melatonin and a low dose of quetiapine can help people with psychiatric disorders sleep better compared to a placebo.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 16 Years to 64 Years |
| Sex | All |
| Enrollment | 255 (estimated) |
| Sponsor | University of Copenhagen Academic / other |
| Locations | 1 site (Copenhagen NV) |
| Status | Recruiting |
| Started | September 18, 2023 |
| Main results expected | February 28, 2029 |
| Study ends | February 28, 2029 |
| Registry record updated | April 24, 2025 |
| Trial ID | NCT06062953 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 16 to 64 with a diagnosed psychiatric disorder and self-reported sleep difficulties occurring at least three times a week.
✕Probably not a fit
Patients currently receiving treatment with melatonin or quetiapine, or those with severe comorbidities or substance dependency, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of melatonin and low-dose quetiapine compared to a placebo in treating insomnia among patients with psychiatric disorders. It is a randomized, blinded, three-armed, placebo-controlled trial designed to assess not only the improvement in sleep but also the overall symptom severity, sleep quality, psychosocial functioning, and subjective well-being of participants. Over a six-week treatment period, participants will receive either melatonin, quetiapine, or a placebo, followed by a brief tapering phase. The study aims to provide insights into how these treatments can alleviate insomnia in this specific patient population.
Why it matters
Potential benefit: If successful, this study could provide effective treatment options for insomnia in patients with psychiatric disorders, improving their overall quality of life.
How similar studies have gone: Previous studies have shown promise in using melatonin for sleep disorders, but the combination with low-dose quetiapine in this specific population is a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 16 to 64 years of age * ICD-10 diagnosis of a current or previous mental or behavioral disorder (F20-F69, F84, F90-95) * For the diagnoses F84 and F90 a previous period of treatment with melatonin is required * For the 16-17 years old: Non-pharmacological treatment options including sleep hygiene education, weighted blanket or other gravity products have been tested with insufficient effect * Self-reported sleep difficulties at least three times per week in the preceding 3 months * Insomnia Severity Index score ≥11 * Women of childbearing potential: negative pregnancy test at baseline and use of highly effective contraception measures * Informed consent Exclusion Criteria: * Current treatment with melatonin or quetiapine * Severe somatic comorbidity * BMI ≥ 35 kg/m2 * Breastfeeding * Alcohol and/or substance dependency within the last 3 months * Inadequate Danish language skills * Not able to make an informed consent * Increased cardiac risk as assessed by presence of cardiac risk factors, cardiac symptoms, or prolonged QT-interval at baseline ECG
Where it's running
-
Mental Health Center Copenhagen
Copenhagen NV, Denmark Recruiting
Study contacts
- Principal investigator: Lone Baandrup, MD — Mental Health Center Copenhagen
- Study coordinator: Lone Baandrup, MD
- Email: lone.baandrup@regionh.dk
- Phone: +4591165903
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lemborexant for insomnia in people with psychiatric conditions
We will try lemborexant for 8 weeks in adults with psychiatric disorders who have insomnia to see if it helps them sleep better and is safe.
-
SleepCogni for children with chronic insomnia
A handheld SleepCogni device is tested to see if it helps kids aged 6–16 with chronic insomnia sleep better.
-
Music therapy after stroke
This trial tests whether adding music therapy to standard care helps stroke patients sleep better and feel less anxious or depressed while in the hospital.
-
Remote ischemic conditioning for post-stroke insomnia
A 136-person, randomized study will test whether a non-invasive arm-cuff procedure done twice daily for 90 days can improve sleep after a first ischemic stroke in adults 18–80.
-
Nurse-guided app-based brief behavioral therapy for insomnia in older adults
Aging adults with insomnia will be asked to try a nurse-supported, smartphone app therapy for four weeks to see if it helps with sleep.
-
Three rTMS approaches to lessen insomnia-related pain after exercise-induced muscle soreness
This study tests whether three different rTMS approaches can reduce pain sensitivity and improve recovery in adults with insomnia after inducing muscle soreness from exercise.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.